NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. SEE TECHNICAL COMMENTS IN THE CHARETS. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
AMKR: Shares Float is 101.18 million
Amkor Technology, Inc. (AMKR), a leading provider of semiconductor packaging and test services, will participate in Deutsche Bank’s 25th Annual Leveraged Finance Conference on Tuesday, October 3, 2017. Amkor’s presentation will occur at 10:00 am Pacific Time (1:00 pm Eastern Time) at The Phoenician, in Scottsdale, AZ.
IMGN: Shares float of 110.41 million.
BLPH: Shares float of 29.51 million.
Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, announced today that it has entered into a definitive securities purchase agreement with new and existing investors to raise aggregate gross proceeds of approximately $23.4 million through a private placement.
AXTI: Shares float of 36.51 million.
News from 2 weeks ago continues to bolster the stock price. AXT, Inc. (AXTI), a leading manufacturer of compound semiconductor substrates, today announced that it has completed the purchase of its new manufacturing facility in the city of Dingxing in the People's Republic of China.
AGEN: Shares float of 51.51 million.
On September 13th, 2017, AGEN announced GSK's shingles vaccine candidate, Shingrix, containing Agenus' proprietary immune adjuvant, QS-21 Stimulon®, was unanimously recommended for approval by the FDA Vaccines and Related Biological Products Advisory Committee. A Biologics License Applications (BLA) filed with the FDA by GSK for Shingrix is under regulatory review. As per management, The Advisory Committee's recommendation for the approval of Shingrix marks the first for a product that includes Agenus' proprietary immune adjuvant, QS-21 Stimulon, and serves as a significant validation.